| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Casselgren, Carl Johan, et al.
(författare)
-
Extending partial edge colorings of Cartesian products of graphs
- 2024
-
Ingår i: Discussiones Mathematicae. Graph Theory. - : UNIV ZIELONA GORA. - 1234-3099 .- 2083-5892.
-
Tidskriftsartikel (refereegranskat)abstract
- We consider the problem of extending partial edge colorings of Cartesian products of graphs. More specifically, we suggest the following Evans -type conjecture. If G is a graph where every precoloring of at most k precolored edges can be extended to a proper chi 0(G)-edge coloring, then every precoloring of at most k + 1 edges of G ?K2 is extendable to a proper (chi'(G) + 1)edge coloring of G ?K2. In this paper we verify that this conjecture holds for trees, complete and complete bipartite graphs, as well as for graphs with small maximum degree. We also prove versions of the conjecture for general regular graphs where the precolored edges are required to be independent.
|
|
| 5. |
- Musa, Ahmed M, et al.
(författare)
-
Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa : A Randomized, Controlled, Multicountry Trial.
- 2022
-
Ingår i: Clinical Infectious Diseases. - : Oxford University Press (OUP). - 1058-4838 .- 1537-6591. ; 76:3, s. e1177-e1185
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visceral leishmaniasis in eastern Africa.METHODS: An open-label, phase 3, randomized, controlled trial was conducted in adult and pediatric patients at 7 sites in eastern Africa. Patients were randomly assigned to either 20 mg/kg paromomycin plus allometric dose of miltefosine (14 days), or 20 mg/kg sodium stibogluconate plus 15 mg/kg paromomycin (17 days). The primary endpoint was definitive cure after 6 months.RESULTS: Of 439 randomized patients, 424 completed the trial. Definitive cure at 6 months was 91.2% (155 of 170) and 91.8% (156 of 170) in the PM/MF and SSG/PM arms in primary efficacy modified intention-to-treat analysis (difference, 0.6%; 97.5% confidence interval [CI], -6.2 to 7.4), narrowly missing the noninferiority margin of 7%. In the per-protocol analysis, efficacy was 92% (149 of 162) and 91.7% (155 of 169) in the PM/MF and SSG/PM arms (difference, -0.3%; 97.5% CI, -7.0 to 6.5), demonstrating noninferiority. Treatments were well tolerated. Four of 18 serious adverse events were study drug-related, and 1 death was SSG-related. Allometric dosing ensured similar MF exposure in children (<12 years) and adults.CONCLUSIONS: PM/MF and SSG/PM efficacies were similar, and adverse drug reactions were as expected given the drugs safety profiles. With 1 less injection each day, reduced treatment duration, and no risk of SSG-associated life-threatening cardiotoxicity, PM/MF is a more patient-friendly alternative for children and adults with primary visceral leishmaniasis in eastern Africa. Clinical Trials Registration. NCT03129646.
|
|
| 6. |
|
|
